BR112021024447A2 - Angioedema treatments - Google Patents

Angioedema treatments

Info

Publication number
BR112021024447A2
BR112021024447A2 BR112021024447A BR112021024447A BR112021024447A2 BR 112021024447 A2 BR112021024447 A2 BR 112021024447A2 BR 112021024447 A BR112021024447 A BR 112021024447A BR 112021024447 A BR112021024447 A BR 112021024447A BR 112021024447 A2 BR112021024447 A2 BR 112021024447A2
Authority
BR
Brazil
Prior art keywords
treatments
angioedema
aenh
demand
present
Prior art date
Application number
BR112021024447A
Other languages
Portuguese (pt)
Inventor
Andreas Maetzel
Martyn Yea Christopher
Paul Feener Edward
David Smith Michael
Louise Marsh Sally
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of BR112021024447A2 publication Critical patent/BR112021024447A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

tratamentos de angioedema. a presente invenção refere-se a tratamentos de angioedema, e especificamente a angioedema mediado por bradicinina não hereditário (bk-aenh). em particular, a presente invenção apresenta tratamentos sob demanda de angioedema mediado por bradicinina não hereditária (bk-aenh) mediante a administração oral de um inibidor de calicreína do plasma a um paciente em necessidade do mesmo sob demanda. tratamentos regulares (ou contínuos) de bk-aenh também são apresentados.angioedema treatments. The present invention relates to treatments of angioedema, and specifically to non-hereditary bradykinin-mediated angioedema (bk-aenh). in particular, the present invention provides on-demand treatments of non-hereditary bradykinin (bk-aenh)-mediated angioedema by oral administration of a plasma kallikrein inhibitor to a patient in need thereof on demand. regular (or ongoing) bk-aenh treatments are also featured.

BR112021024447A 2019-06-14 2020-06-15 Angioedema treatments BR112021024447A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962861758P 2019-06-14 2019-06-14
GBGB1910125.2A GB201910125D0 (en) 2019-07-15 2019-07-15 Treatments of angioedema
PCT/GB2020/051441 WO2020249979A1 (en) 2019-06-14 2020-06-15 Treatments of angioedema

Publications (1)

Publication Number Publication Date
BR112021024447A2 true BR112021024447A2 (en) 2022-01-18

Family

ID=67700187

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021024447A BR112021024447A2 (en) 2019-06-14 2020-06-15 Angioedema treatments

Country Status (17)

Country Link
US (1) US20220226293A1 (en)
EP (1) EP3982961A1 (en)
JP (1) JP2022537913A (en)
KR (1) KR20220024221A (en)
CN (1) CN113993520A (en)
AR (1) AR119159A1 (en)
AU (1) AU2020293616A1 (en)
BR (1) BR112021024447A2 (en)
CA (1) CA3142220A1 (en)
CL (2) CL2021003243A1 (en)
GB (1) GB201910125D0 (en)
IL (1) IL288612A (en)
MA (1) MA56188A (en)
MX (1) MX2021014558A (en)
SG (1) SG11202113375PA (en)
TW (1) TW202112371A (en)
WO (1) WO2020249979A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
EP4288036A1 (en) 2022-04-27 2023-12-13 Kalvista Pharmaceuticals Limited Formulations of a plasma kallikrein inhibitor
CN116003386B (en) * 2022-11-20 2024-03-26 药康众拓(北京)医药科技有限公司 Deuterated N-benzyl pyridone pyrazole carboxamides, pharmaceutical composition and application

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (en) 1993-06-03 1993-06-03 Ab Astra NEW PEPTIDE DERIVATIVES
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
CA2658523C (en) 2006-07-31 2012-06-12 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
DE102006050672A1 (en) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh New glycylglycine derivatives with a benzylsulfonylamido group and an amidino-organylamido group at the opposite chain ends, used in drugs for reducing loss of blood, e.g. in operations
JP2013121919A (en) 2010-03-25 2013-06-20 Astellas Pharma Inc Plasma kallikrein inhibitor
US8921319B2 (en) 2010-07-07 2014-12-30 The Medicines Company (Leipzig) Gmbh Serine protease inhibitors
WO2012009009A2 (en) 2010-07-14 2012-01-19 Addex Pharma S.A. Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
HUE057851T2 (en) 2013-05-23 2022-06-28 Kalvista Pharmaceuticals Ltd Inhibitors of plasma kallikrein
GB201421083D0 (en) * 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201721515D0 (en) * 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor

Also Published As

Publication number Publication date
MX2021014558A (en) 2022-04-06
CL2021003243A1 (en) 2022-09-30
GB201910125D0 (en) 2019-08-28
KR20220024221A (en) 2022-03-03
MA56188A (en) 2022-04-20
EP3982961A1 (en) 2022-04-20
WO2020249979A1 (en) 2020-12-17
US20220226293A1 (en) 2022-07-21
IL288612A (en) 2022-02-01
CA3142220A1 (en) 2020-12-17
AU2020293616A1 (en) 2022-01-27
SG11202113375PA (en) 2021-12-30
CN113993520A (en) 2022-01-28
TW202112371A (en) 2021-04-01
JP2022537913A (en) 2022-08-31
CL2023000699A1 (en) 2023-10-30
AR119159A1 (en) 2021-12-01

Similar Documents

Publication Publication Date Title
BR112021024447A2 (en) Angioedema treatments
CL2021003244A1 (en) hereditary angioedema treatments
WO2018067512A8 (en) Spirocyclic compounds
EA201891200A1 (en) COMPOSITIONS CONTAINING BACTERIAL STRAINS
NI201500024A (en) ANTIBODIES AND VACCINES TO BE USED IN THE TREATMENT OF ROR1 CANCERS AND TO INHIBIT METASTASIS.
MA40404A (en) Combination therapy for treating a paramyxovirus
BR112019007977A2 (en) compound, pharmaceutical composition, method of treating or preventing cancer, and use of a compound
BR112016005286A2 (en) compositions and methods comprising lg12 clade protease variants
PH12014501122A1 (en) Methods of treatment using an antibody against interferon gamma
SG10201903119QA (en) Polypeptide vaccine
AU2016316202A8 (en) Molecular constructs for preventing the formation of blood clot and/or treating thrombosis
MX2021007773A (en) Egfr inhibitor compounds.
BR112015023207A8 (en) cynin compositions and methods for the prevention and treatment of disorders associated with c1 esterase inhibitor deficiency.
BR112016016274A2 (en) BLOOD-BRAIN BARRIER BRIDGE
BR112017021312A2 (en) Lung cancer treatment with glutaminase inhibitors
UA116999C2 (en) Anti-hemagglutinin antibodies and methods of use
TR201901077T4 (en) Combined Preparations for Cancer or Infection Treatment
BR112017018522A2 (en) compositions and methods for cancer diagnosis and treatment
BR112018011622A2 (en) method to treat hereditary angioedema attack (hae) or reduce hae attack rate
BR112017017060A2 (en) ?treatment?
EA201790312A1 (en) COMBINATION OF MEDICINES FOR THE TREATMENT OF MULTIPLE MYELOMA
MX2017012553A (en) Spirocyclic compounds.
BR112019004594A2 (en) gene therapy for patients with fanconi anemia
BR112018003836A2 (en) btk inhibitor combinations to treat multiple myeloma
PH12018501943A1 (en) Pharmaceutical compositions for the treatment of cancer